Thalidomide neuropathy in patients treated for metastatic prostate cancer

• Published in: Muscle & nerve Vol. 24; no. 8; pp. 1050 - 1057
• Main Authors: Molloy, F.M., Floeter, M.K., Syed, N.A., Sandbrink, F., Culcea, E., Steinberg, S.M., Dahut, W., Pluda, J., Kruger, E.A., Reed, E., Figg, W.D.
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 01.08.2001; Wiley
• Subjects: Action Potentials - drug effects; Age Factors; Aged; Aged, 80 and over; Biological and medical sciences; Brachial Plexus - drug effects; Brachial Plexus - physiopathology; Cohort Studies; Dose-Response Relationship, Drug; Drug toxicity and drugs side effects treatment; Electrodiagnosis; Electromyography; Follow-Up Studies; Humans; Male; Medical sciences; Middle Aged; Neoplasm Metastasis; nerve conduction studies; Neural Conduction - drug effects; Neurons, Afferent - drug effects; neuropathy; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - diagnosis; Pharmacology. Drug treatments; Prospective Studies; Prostatic Neoplasms - drug therapy; Risk Factors; Sural Nerve - drug effects; Sural Nerve - physiopathology; thalidomide; Thalidomide - adverse effects; toxicity; Toxicity: nervous system and muscle; Human; Nervous system diseases; Prostate disease; Toxicity; Action potential; Malignant tumor; Peripheral neuropathy; Nerve conduction; Electrodiagnosis; Chemotherapy; Treatment; Sensory nerve; Thalidomide
• ISSN: 0148-639X; 1097-4598
• DOI: 10.1002/mus.1109

We prospectively evaluated thalidomide‐induced neuropathy using electrodiagnostic studies. Sixty‐seven men with metastatic androgen‐independent prostate cancer in an open‐label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3‐month intervals during treatment. NCS included recording of sensory nerve action potentials (SNAPs) from median, radial, ulnar, and sural nerves. SNAP amplitudes for each nerve were expressed as the percentage of its baseline, and the mean of the four was termed the SNAP index. A 40% decline in the SNAP index was considered clinically significant. Thalidomide was discontinued in 55 patients for lack of therapeutic response. Of 67 patients initially enrolled, 24 remained on thalidomide for 3 months, 8 remained at 6 months, and 3 remained at 9 months. Six patients developed neuropathy. Clinical symptoms and a decline in the SNAP index occurred concurrently. Older age and cumulative dose were possible contributing factors. Neuropathy may thus be a common complication of thalidomide in older patients. The SNAP index can be used to monitor peripheral neuropathy, but not for early detection. © 2001 John Wiley & Sons, Inc. Muscle Nerve 24: 1050–1057, 2001